dailyloe.com – Hims & Hers Health stock climbed as much as 11% on Monday, April 20, 2026, continuing a week-long rally. The surge followed an FDA announcement about easing peptide regulation. This push has been repeatedly championed by Robert F. Kennedy Jr. The stock has surged more than 125% since its lows in February.
The rally began last week after the FDA announced a July meeting. The meeting will consider easing regulation around peptides. Peptides include regulated GLP-1 drugs and gray-market injectables. These injectables promise better skin, faster healing, and slower aging.
On April 15, Health Secretary Robert F. Kennedy Jr. made an announcement. The FDA will evaluate removing 12 peptides from its restrictions. The FDA had restricted 19 peptides in 2023 citing health risks. This could clear a path for telehealth platforms like Hims.
RFK Jr. has long been a loud proponent of peptides. He claimed on Joe Rogan’s podcast in February that he benefited personally. He said he has personally benefited from using peptides. This advocacy has coincided with the stock’s movement.
Hims acquired a California-based peptide manufacturing facility in February 2025. This positioned the company to produce peptide therapies at scale. Production would depend on regulators green-lighting the category. The facility acquisition was a strategic move.
Hims & Hers built its business on direct-to-consumer prescriptions. It treats conditions like hair loss and erectile dysfunction. It also addresses mental health and skincare. Its breakout growth came from selling compounded GLP-1 drugs.
The company sold compounded versions during weight-loss drug shortages. Shortages affected Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound around 2024. This strategy fueled a 59% revenue increase in 2025. Revenue reached $2.35 billion but brought risk.
This growth exposed the company to significant regulatory and legal risk. An initial partnership with Novo Nordisk collapsed in April 2025. It collapsed within two months after Novo accused Hims of deceptive promotion. Novo called Hims’s versions knockoff Wegovy drugs.
The accusation set off nearly a year of litigation and FDA warning letters. It also led to public feuding between the companies. In March, the situation with Hims and the regulatory landscape continued evolving. The recent FDA announcement has shifted market sentiment.
